Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPE | Q05469 | 3/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 5/20 | 0.32 |
| ▸ | ELOVL1 | Q9BW60 | 3/20 | 0.32 |
| ▸ | DHODH | Q02127 | 2/20 | 0.32 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.31 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
| ▸ | MMP13 | P45452 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30494523 | 1.00 | LIPE (0.37) | LIPECYP11B1LRRK2ELOVL1DHODH | |
| SCHEMBL29048010 | 0.87 | ELOVL1 (0.33) | ELOVL1DPP4MMP13 | |
| SCHEMBL24253760 | 0.87 | TPH1 (0.41) | LIPE | |
| SCHEMBL24253553 | 0.87 | TPH1 (0.41) | LIPE | |
| SCHEMBL24253761 | 0.87 | TPH1 (0.41) | LIPE | |
| SCHEMBL24253624 | 0.85 | ELOVL1 (0.37) | ELOVL1DPP4MMP13 | |
| SCHEMBL24253755 | 0.85 | LIPE (0.36) | LIPEDHODHFFAR4 | |
| SCHEMBL30494554 | 0.85 | LIPE (0.36) | LIPEDHODHFFAR4 | |
| SCHEMBL24253754 | 0.85 | LIPE (0.36) | LIPEDHODHFFAR4 | |
| SCHEMBL30494531 | 0.85 | LIPE (0.36) | LIPEDHODHFFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11708366-B2 | Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof | NOVARTIS AG (CH) | 2023-07-25 | — | — | US | disclosed |
| US-11708366-B2 | Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof | NOVARTIS AG (CH) | 2023-07-25 | — | — | US | disclosed |
| US-20220048909-A1 | HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11708366-B2 | Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof | REN, NR3C2, PKD1 | LIPE 3955/4885CYP11B1 17/4885LRRK2 456/4885 |
| US-20220048909-A1 | HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF | REN, NR3C2, PKD1 | LIPE 3955/4885CYP11B1 17/4885LRRK2 456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.